Alnylam (ALNY) Gets Positive CHMP Opinion for Lumasiran

Alnylam Pharmaceuticals, Inc. ALNY announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of its RNAi candidate, lumasiran, targeting the hydroxyacid oxidase 1 (HAO1) mRNA — encoding glycolate oxidase (GO) — in development for the treatment of primary hyperoxaluria type 1 (PH1). The ultra-rare disease causes a progressive decline in kidney function and can lead to end-stage renal disease. Lumasiran will be marketed in Europe under the brand name Oxlumo. A decision by the European Commission is expected in the fourth quarter of 2020.

Shares of Alnylam have gained 26.3% year to date against the industry’s decline of 0.2%.

The positive opinion is supported by the efficacy and safety findings of Oxlumo in PH1 patients, including data from both ILLUMINATE-A and ILLUMINATE-B phase III studies. Key primary and secondary endpoints included the reduction of urinary and plasma oxalate and the proportion of patients achieving normalization or near-normalization of urinary oxalate in response to Oxlumocomparedto placebo. 

The candidate also enjoys the Priority Medicines (PRIME) designation by the EMA andthe Orphan Drug designation in the European Union.Alnylam filed a new drug application (NDA) with the FDA. The FDA has granted a Priority Review for the NDA and set an action date of Dec 3, 2020.

Meanwhile, the company is also evaluating several other candidates. A few significant ones include vutrisiran andinclisiran. The company and partner NovartisNVS inclisiranis under review in the United States and Europe for treating heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease.

Alnylam has a collaboration with Regeneron Pharmaceuticals REGN to discover, develop and commercialize new RNAi therapeutics for a broad range of diseases by addressing disease targets expressed in the liver, eye and central nervous system.

Zacks Rank and Stock to Consider

Alnylam currently carries a Zacks Rank #3 (Hold).

A better-ranked stock in the healthcare sector includes Emergent Biosolutions Inc. EBS, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Emergent’s earnings estimates have increased from $4.23 to $6.61 for 2020 and from $5.55 to $8.42 for 2021 over the past 90 days. Shares of the company have increased 83.2% year to date.


Alnylam Pharmaceuticals, Inc. Price

Alnylam Pharmaceuticals, Inc. Price

Alnylam Pharmaceuticals, Inc. price | Alnylam Pharmaceuticals, Inc. Quote

Zacks’ Single Best Pick to Double

From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, SherazMian hand-picks one to have the most explosive upside of all. With users in 180 countries and soaring revenues, it’s set to thrive on remote working long after the pandemic ends. No wonder it recently offered a stunning $600 million stock buy-back plan. The sky’s the limit for this emerging tech giant. And the earlier you get in, the greater your potential gain.

Click Here, See It Free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report
Novartis AG (NVS): Free Stock Analysis Report
Emergent Biosolutions Inc. (EBS): Free Stock Analysis Report
To read this article on click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics


Latest Markets Videos


Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

Learn More